Last reviewed · How we verify

NCT00777712: WoundVac

Mechanisms Underlying Impaired Diabetic Wound Healing

Recruiting now Last updated 3 June 2025
What this trial tests

trial testing Blood draw in Non-healing Wounds in 250 participants. Currently enrolling.

Timeline
1 September 2008
Primary endpoint
31 December 2029
31 December 2030

Quick facts

Lead sponsorUniversity of Pittsburgh
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment250
Start date1 September 2008
Primary completion31 December 2029
Estimated completion31 December 2030
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Pittsburgh

Who can join

Adults 21 to 80, any sex, with Non-healing Wounds or Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals with diabetes. Biology of normal (peripheral blood derived cells) versus wound derived cells will also be studied.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Advances in nucleic acid delivery strategies for diabetic wound therapy.
    Sarthi S, Bhardwaj H, Kumar Jangde R. · · 2024 · cited 4× · PMID 39286540 · DOI 10.1016/j.jcte.2024.100366

Verify or expand the search:

Other trials of Blood draw

Trials testing the same drug.

Other University of Pittsburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00777712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing